The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy

The current standard of care for glioblastoma (GBM) is maximal surgical resection with adjuvant radiotherapy and temozolomide (TMZ). As the 5-year survival with GBM remains at a dismal <10%, novel therapies are needed. Immunotherapies such as the dendritic cell (DC) vaccine, heat shock protein va...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Mira A., Kim, Jennifer E., Ruzevick, Jacob, Li, Gordon, Lim, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276952/
https://www.ncbi.nlm.nih.gov/pubmed/25268164
http://dx.doi.org/10.3390/cancers6041953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276952/
https://www.ncbi.nlm.nih.gov/pubmed/25268164
http://dx.doi.org/10.3390/cancers6041953

Ejemplares similares